Nathan Herrmann

4.4k total citations · 1 hit paper
62 papers, 3.2k citations indexed

About

Nathan Herrmann is a scholar working on Pharmacology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Nathan Herrmann has authored 62 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pharmacology, 23 papers in Psychiatry and Mental health and 9 papers in Physiology. Recurrent topics in Nathan Herrmann's work include Cholinesterase and Neurodegenerative Diseases (17 papers), Treatment of Major Depression (17 papers) and Dementia and Cognitive Impairment Research (15 papers). Nathan Herrmann is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (17 papers), Treatment of Major Depression (17 papers) and Dementia and Cognitive Impairment Research (15 papers). Nathan Herrmann collaborates with scholars based in Canada, United States and United Kingdom. Nathan Herrmann's co-authors include Krista L. Lanctôt, Claudio A. Naranjo, Paolo Mazzotta, Usoa E. Busto, Kenneth I. Shulman, Scott E. Walker, Sandra E. Black, Mario Masellis, Chris Heyn and Ying Meng and has published in prestigious journals such as Nature Communications, PLoS ONE and Biological Psychiatry.

In The Last Decade

Nathan Herrmann

61 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound

2018 666 citations Mario Masellis, Nathan Herrmann et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan Herrmann Canada	25	779	592	526	458	445	62	3.2k
F. Müller‐Spahn Switzerland	44	1.2k 1.6×	622 1.1×	218 0.4×	1.6k 3.4×	353 0.8×	124	5.2k
Carlos Ribeiro Portugal	37	273 0.4×	328 0.6×	246 0.5×	537 1.2×	310 0.7×	191	4.2k
Yuping Ning China	38	1.4k 1.7×	1.3k 2.1×	187 0.4×	496 1.1×	1.4k 3.1×	344	5.5k
Shinichiro Nakajima Japan	35	1.5k 1.9×	491 0.8×	100 0.2×	560 1.2×	953 2.1×	205	4.3k
Scott A. Small United States	36	1.7k 2.2×	193 0.3×	618 1.2×	956 2.1×	336 0.8×	70	5.7k
Robert C. Smith United States	33	1.3k 1.6×	283 0.5×	78 0.1×	402 0.9×	250 0.6×	124	3.6k
Huaning Wang China	35	505 0.6×	308 0.5×	82 0.2×	368 0.8×	529 1.2×	178	4.0k
Sokratis G. Papageorgiou Greece	27	1.0k 1.3×	407 0.7×	71 0.1×	1.0k 2.3×	114 0.3×	166	3.7k
Mirosław Bryś United States	27	1.3k 1.7×	295 0.5×	102 0.2×	2.3k 4.9×	199 0.4×	47	3.9k
Sujung Yoon South Korea	33	582 0.7×	371 0.6×	48 0.1×	623 1.4×	362 0.8×	114	4.2k

Countries citing papers authored by Nathan Herrmann

Since Specialization

Citations

This map shows the geographic impact of Nathan Herrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Herrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Herrmann more than expected).

Fields of papers citing papers by Nathan Herrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Herrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Herrmann. The network helps show where Nathan Herrmann may publish in the future.

Co-authorship network of co-authors of Nathan Herrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Herrmann. A scholar is included among the top collaborators of Nathan Herrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Herrmann. Nathan Herrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brooks, Heather, Clement Ma, Alina Lee, et al.. (2025). Impact of Transcranial Direct Current Stimulation–Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial. Biological Psychiatry. 1 indexed citations

Beroncal, Erika L., Heather Brooks, James L. Kennedy, et al.. (2024). Exploring mitochondrial blood-based and genetic markers in older adults with mild cognitive impairment and remitted major depressive disorder. Translational Psychiatry. 14(1). 457–457. 2 indexed citations

Chan, Brian, Che‐Yuan Wu, Michelle Nguyen, et al.. (2021). Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis. Brain Behavior and Immunity. 100. 55–69. 47 indexed citations

Lanctôt, Krista L., et al.. (2019). Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. Drugs & Aging. 36(7). 589–605. 18 indexed citations

Rochon, Paula A., Andrea Gruneir, Chaim M. Bell, et al.. (2018). Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study. PLoS ONE. 13(10). e0205524–e0205524. 21 indexed citations

Desmarais, Philippe, Jonathan D. Rohrer, Quôc Dinh Nguyên, et al.. (2018). Therapeutic trial design for frontotemporal dementia and related disorders. Journal of Neurology Neurosurgery & Psychiatry. 90(4). 412–423. 12 indexed citations

Mohammad, Dana, et al.. (2017). Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert Opinion on Drug Safety. 16(9). 1009–1019. 58 indexed citations

Liu, Celina S., Myuri Ruthirakuhan, Sarah Chau, et al.. (2016). Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. Current Alzheimer Research. 13(10). 1134–1144. 20 indexed citations

Shulman, Kenneth I., Nathan Herrmann, & Scott E. Walker. (2013). Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs. 27(10). 789–797. 171 indexed citations

10.

Herrmann, Nathan, et al.. (2011). Transdermal Rivastigmine. CNS Drugs. 25(7). 575–583. 20 indexed citations

11.

Herrmann, Nathan, et al.. (2009). Persistence with Cholinesterase Inhibitor Therapy for Dementia. Drugs & Aging. 26(5). 403–407. 35 indexed citations

12.

Fischer, Hadas D., Paula A. Rochon, Sudeep S. Gill, et al.. (2008). Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. Journal of Clinical Epidemiology. 61(11). 1152–1160. 22 indexed citations

13.

Valiyeva, Elmira, Nathan Herrmann, Paula A. Rochon, S.S. Gill, & G. M. Anderson. (2008). Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. Canadian Medical Association Journal. 179(5). 438–446. 86 indexed citations

14.

Herrmann, Nathan. (2007). Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 34(S1). S103–S108. 8 indexed citations

15.

Cairney, John, et al.. (2007). Epidemiology of Social Phobia in Later Life. American Journal of Geriatric Psychiatry. 15(3). 224–233. 50 indexed citations

16.

Hall, Judith, Claudio A. Naranjo, Beth Sproule, & Nathan Herrmann. (2003). Pharmacokinetic and Pharmacodynamic Evaluation of the Inhibition of Alprazolam by Citalopram and Fluoxetine. Journal of Clinical Psychopharmacology. 23(4). 349–357. 19 indexed citations

17.

Herrmann, Nathan. (2002). Pharmacotherapy for Alzheimerʼs disease and other dementias. Current Opinion in Psychiatry. 15(4). 403–409. 3 indexed citations

18.

Naranjo, Claudio A., et al.. (2002). Brain Reward System Activity in Major Depression and Comorbid Nicotine Dependence. Journal of Pharmacology and Experimental Therapeutics. 302(3). 1265–1271. 41 indexed citations

19.

Özdemir, Vural, Claudio A. Naranjo, Nathan Herrmann, et al.. (1997). Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo*. Clinical Pharmacology & Therapeutics. 62(3). 334–347. 67 indexed citations

20.

Herrmann, Nathan, Joachim‐Hermann Scharf, B. Böwing, & Kneginja Richter. (1988). Klinische Relevanz des Trachealbronchus. Klinische Pädiatrie. 200(1). 20–25. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact